[PRNewswire] Merck Advances Oncology Portfolio and Pipeline with New and

— New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO(R)* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer — Overall [전체본문 2020-09-14 10:05:00Z]